Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18 F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, microglial activation may also be protective in these neurodegenerative conditions, for example by enhancing microglia phagocytosis of amyloid plaques in the context of AD (176–178).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [177]
In the citing paper
“High CSF sTREM2 was associated with slower rates of Aβ accumulation”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade of pathological brain changes resulting in the occurrence of dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy, 2016).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In 5×FAD mice which show Ab deposition in the hippocampus and cortex by 6 months of age (Oakley et al, 2006), knockdown of the TREM2 gene decreased microglia activation but increased amyloid plaque load at ages 8 months in the hippocampus (Wang et al, 2015) and cortex (Griciuc et al, 2019).”
BackgroundComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al, 2016).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…that alterations in the innate immune system are associated with enhanced risk of AD and thus modulate the development of AD (Lambert et al, 2009; Guerreiro et al, 2013; Jonsson et al, 2013; Reitz et al, 2013; Efthymiou & Goate, 2017; Sims 1 Institute for Stroke and Dementia Research (ISD),…”
BackgroundSelf-citationKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
Self-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“…normal (CN, MMSE > 24, CDR = 0, non-depressed), mild cognitively impaired (MCI; MMSE > 24, CDR = 0.5, objective memory-loss on the education adjusted Wechsler Memory Scale II, preserved activities of daily living) or AD dementia following standard diagnostic criteria (Petersen et al, 2010).”
InfluentialSelf-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“…humans showed that rare variants in the TREM2 gene are associated with an exceptionally increased risk of AD, comparable to increase in risk by the APOE e4 genotype (Guerreiro & Hardy, 2013; Jonsson et al, 2013), suggesting that TREM2-related microglia activation may reduce the risk of AD dementia.”
BackgroundVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 12: e12308 | 2020 1 of 14 et al, 2017; Jansen et al, 2019).”
MethodInfluentialInflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“…neuroinflammation in AD are complex and heterogenous involving multiple pathways (e.g., IL6, IL-1b, and YKL-40) and several studies suggest that microglia activation can have adverse effects in AD (Llorens et al, 2017; Kinney et al, 2018; Gotzl et al, 2019; for review, see Butovsky & Weiner, 2018).”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“Causal gene expression network analysis showed the TREM2/DAP12 complex as a key regulator hub for microglia gene expression in AD (Zhang et al, 2013; Wang et al, 2015; Keren-Shaul et al, 2017; Parhizkar et al, 2019).”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 1×
“Specifically, we obtained both 18F GE-180 TSPO microglia PET and 18F-florbetaben amyloid PET in the AppNL-G-F mice, which show global Ab deposition at 4 months of age (Saito et al, 2014), reaching a plateau by 9 months of age (Mehla et al, 2019).”
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314 · cited 1×
“However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al, 2016).”
BackgroundPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 1×
“Detailed protocols can be found on the ADNI homepage and in previous publications (Scholl et al, 2016).”
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046 · cited 4×
“Microglia activation involves the phagocytosis of amyloid plaques as well as a reduction in Abneurotoxicity and thus plays a key role to restore brain homeostasis (Sarlus & Heneka, 2017; Butovsky & Weiner, 2018).”
BackgroundResultInfluentialARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Self-citationRelationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 2×
“Furthermore, although CSF sTREM2 levels may reflect the amount of signaling-competent TREM2 on the surface of microglia (Kleinberger et al, 2014; Schlepckow et al, 2017) and thus provide a marker of microglia activation, the link between CSF sTREM2 and microglia activation is not firmly established.”
BackgroundSelf-citationTREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Impact of multiple pathologies on the threshold for clinically overt dementia
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1717-7 · Cited by 739 · cited 1×
“…between higher microglia activation and lower Ab accumulation in a more controlled setting, i.e., in the absence of potentially confounding co-pathologies such as vascular changes that may drive microglia activation in patients with AD, where mixed pathologies are frequent (Kapasi et al, 2017).”
BackgroundCalcia, M. A., Bonsall, D. R., Bloomfield, P. S., Selvaraj, S., Barichello, T., & Howes, O. D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4218-9 · Cited by 709
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“…is consistent with the proposal that any TREM2-dependent beneficial effects on amyloid are stage-dependent and occur preferentially at later stages of Ab (Jay et al, 2017), which may explain why some studies did not find a beneficial effect of TREM2 on Ab (Jay et al, 2015; Krasemann et al, 2017).”
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0296-9 · Cited by 555
Self-citationT. Griffin, W. S., Sheng, J. G., Roberts, G. W., & Mrak, R. E. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199503000-00014 · Cited by 549
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationHamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
Leyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · cited 2×
“Furthermore, we focus mainly on Ab whereas the evidence for sTREM2 effects on pathologic tau remains preliminary and may be differentially affected by microglia activation (Bemiller et al, 2017; Leyns et al, 2017; Jiang et al, 2018).”
BackgroundComparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., Rabinovici, G. D., & Jagust, W. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.058 · Cited by 462 · cited 1×
“Recorded images were coregistered and averaged across blocks and intensity-normalized to the inferior cerebellar gray (Maass et al, 2017).”
MethodDisease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B. N., Wang, L.-S., Valladares, O., Lin, C.-F., Larson, E. B., Graff-Radford, N. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.2973 · Cited by 431 · cited 1×
“…are associated with enhanced risk of AD and thus modulate the development of AD (Lambert et al, 2009; Guerreiro et al, 2013; Jonsson et al, 2013; Reitz et al, 2013; Efthymiou & Goate, 2017; Sims 1 Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian…”
BackgroundLee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396 · cited 2×
“Our results are in general agreement with previous reports of experimentally increased TREM2 to be associated with lower Ab deposition (Lee et al, 2018), and genetically induced TREM2 deficiency to be associated with higher Ab deposition at a time window of advanced but still accumulating Ab in…”
BackgroundResultTREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease
Griciuc, A., Patel, S., Federico, A. N., Choi, S. H., Innes, B. J., Oram, M. K., Cereghetti, G., McGinty, D., Anselmo, A., Sadreyev, R. I., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.06.010 · Cited by 378 · cited 1×
“In 5×FAD mice which show Ab deposition in the hippocampus and cortex by 6 months of age (Oakley et al, 2006), knockdown of the TREM2 gene decreased microglia activation but increased amyloid plaque load at ages 8 months in the hippocampus (Wang et al, 2015) and cortex (Griciuc et al, 2019).”
BackgroundZhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371
Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deußing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagoz, A., Katzmarski, N., et al. (2019) · doi:10.7892/boris.125653 · Cited by 352
Self-citationTREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury
Mazaheri, F., Snaidero, N., Kleinberger, G., Madore, C., Daria, A., Werner, G., Krasemann, S., Capell, A., Trümbach, D., Wurst, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201743922 · Cited by 351
Self-citationInitiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347
Self-citationCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 1×
“CSF sTREM2 is increased in humans with a biomarker profile of AD years before the onset of dementia symptoms (Heslegrave et al, 2016; Piccio et al, 2016; Suarez-Calvet et al, 2016a,b, 2019), where higher CSF sTREM2 at a given biomarker level of Ab and pathologic tau was associated with larger gray…”
BackgroundSelf-citationTREM2 function impedes tau seeding in neuritic plaques
Leyns, C. E. G., Gratuze, M., Narasimhan, S., Jain, N., Koscal, L. J., Jiang, H., Manis, M., Colonna, M., Lee, V. M. Y., Ulrich, J. D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0433-0 · Cited by 332 · cited 1×
“Interestingly, a recent study in a transgenic mouse model of Ab reported that genetically induced TREM2 deficiency was associated with higher pathologic tau seeding in neurotic plaques (Leyns et al, 2019).”
BackgroundEwers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327
Self-citationPiccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R. E., Fenoglio, C., Rinker, J., Naismith, R. T., Panina-Bordignon, P., Passini, N., et al. (2008) · Brain · doi:10.1093/brain/awn217 · Cited by 307
Self-citationIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · cited 1×
“CSF sTREM2 is increased in humans with a biomarker profile of AD years before the onset of dementia symptoms (Heslegrave et al, 2016; Piccio et al, 2016; Suarez-Calvet et al, 2016a,b, 2019), where higher CSF sTREM2 at a given biomarker level of Ab and pathologic tau was associated with larger gray…”
BackgroundBemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299
Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272
Self-citationThe MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk
Deming, Y., Filipello, F., Cignarella, F., Cantoni, C., Hsu, S., Mikesell, R., Li, Z., Del-Aguila, J. L., Dube, U., Farias, F. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau2291 · Cited by 271 · cited 1×
“Furthermore, a common genetic variant in the 4-domain subfamily gene MS4A4A that is associated with decreased risk of AD was found to be associated with higher CSF sTREM2 levels (Deming et al, 2019), suggesting that higher sTREM2 levels may contribute to a decreased risk of AD.”
BackgroundSelf-citationSchlepckow, K., Kleinberger, G., Fukumori, A., Feederle, R., Lichtenthaler, S. F., Steiner, H., & Haass, C. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707672 · Cited by 261
Self-citationTREM2 and Neurodegenerative Disease
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1306509 · Cited by 254
Kleinberger, G., Brendel, M., Mracsko, E., Wefers, B., Groeneweg, L., Xiang, X., Focke, C., Deußing, M., Suárez‐Calvet, M., Mazaheri, F., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796516 · Cited by 251
Self-citationYKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210 · cited 1×
“The current study is limited with regard to range of AD disease severity, but effects of microglia activation may vary by disease stage as suggested by results from transgenic mice (Jay et al, 2017; Parhizkar et al, 2019; Meilandt et al, 2020) and clinical trials in humans (Leoutsakos et al, 2012).”
Sheng, J. G., Mrak, R. E., & Griffin, W. S. T. (1997) · Acta Neuropathologica · doi:10.1007/s004010050664 · Cited by 190
Hamelin, L., Lagarde, J., Dorothée, G., Potier, M. C., Corlier, F., Kuhnast, B., Caillé, F., Dubois, B., Fillon, L., Chupin, M., et al. (2018) · Brain · doi:10.1093/brain/awy079 · Cited by 177
TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice
Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · cited 1×
“Recent studies on mouse models of tau pathology suggest that that TREM2 deficiency is associated with higher tau pathology (Jiang et al, 2015, 2016), although inconsistent findings have been reported as well (Leyns et al, 2017).”
BackgroundMehla, J., Lacoursiere, S. G., Lapointe, V., McNaughton, B. L., Sutherland, R. J., McDonald, R. J., & Mohajerani, M. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.026 · Cited by 147 · cited 2×
“…e12308 | 2020 ª 2020 The Authors unlikely that ceiling effects of amyloid deposition explain the current results, because in agreement with previous studies (Mehla et al, 2019), the AppNL-G-F mice in the current study showed substantial increase in Florbetaben PET between 5 and 10 months of age.”
MethodResultExercise reduces activation of microglia isolated from hippocampus and brain of aged mice
Kohman, R. A., Bhattacharya, T. K., Wojcik, E., & Rhodes, J. S. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-114 · Cited by 146
Brendel, M., Probst, F., Jaworska, A., Overhoff, F., Korzhova, V., Albert, N. L., Beck, R., Lindner, S., Gildehaus, F.-J., Baumann, K., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167858 · Cited by 145
Self-citationTau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding
Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez‐Vieitez, E., & Nordberg, A. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.007 · Cited by 139
Zhong, L., Chen, X.-F., Zhang, Z.-L., Wang, Z., Shi, X.-Z., Xu, K., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645986 · Cited by 133
Subthreshold Amyloid Predicts Tau Deposition in Aging
Leal, S. L., Lockhart, S. N., Maass, A., Bell, R. K., & Jagust, W. J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0485-18.2018 · Cited by 133
Moore, K. M., Girens, R. E., Larson, S. K., Jones, M. R., Restivo, J. L., Holtzman, D. M., Cirrito, J. R., Yuede, C. M., Zimmerman, S. D., & Timson, B. F. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.11.004 · Cited by 128
Ziegler‐Waldkirch, S., d′Errico, P., Sauer, J., Erny, D., Savanthrapadian, S., Loreth, D., Katzmarski, N., Blank, T., Bartos, M., Prinz, M., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201797021 · Cited by 120
Leoutsakos, J., Muthén, B., Breitner, J. C. S., & Lyketsos, C. G. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2723 · Cited by 119
Prokop, S., Miller, K. R., Labra, S. R., Pitkin, R. M., Hoxha, K., Narasimhan, S., Changolkar, L., Rosenbloom, A., Lee, V. M.-Y., & Trojanowski, J. Q. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02048-2 · Cited by 119
Self-citationGispert, J. D., Suárez‐Calvet, M., Monté, G. C., Tucholka, A., Falcón, C., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.005 · Cited by 118
Self-citationGötzl, J. K., Brendel, M., Werner, G., Parhizkar, S., Sebastian Monasor, L., Kleinberger, G., Colombo, A., Deussing, M., Wagner, M., Winkelmann, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809711 · Cited by 118
Self-citationJiang, T., Tan, L., Zhu, X.-C., Zhou, J.-S., Cao, L., Tan, M.-S., Wang, H.-F., Chen, Q., Zhang, Y.-D., & Yu, J.-T. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.019 · Cited by 111 · cited 1×
“Recent studies on mouse models of tau pathology suggest that that TREM2 deficiency is associated with higher tau pathology (Jiang et al, 2015, 2016), although inconsistent findings have been reported as well (Leyns et al, 2017).”
BackgroundZhang, J., Guo, Y., Wang, Y., Song, L., Zhang, R., & Du, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.025 · Cited by 110
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
Ikonomovic, M. D., Buckley, C. J., Heurling, K., Sherwin, P., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0399-z · Cited by 98
In vivo Imaging of Glial Activation in Alzheimer's Disease
Edison, P., Donat, C. K., & Sastre, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00625 · Cited by 96
Rominger, A., Brendel, M., Burgold, S., Keppler, K., Baumann, K., Xiong, G., Mille, E., Gildehaus, F.-J., Carlsen, J., Schlichtiger, J., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114660 · Cited by 85
Self-citationSheng, L., Chen, M., Cai, K., Song, Y., Yu, D., Zhang, H., & Xu, G. (2019) · The FASEB Journal · doi:10.1096/fj.201900527r · Cited by 83
Thakkar, R., Wang, R., Wang, J., Vadlamudi, R. K., & Brann, D. W. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4248526 · Cited by 67
Brendel, M., Kleinberger, G., Probst, F., Jaworska, A., Overhoff, F., Blume, T., Albert, N. L., Carlsen, J., Lindner, S., Gildehaus, F. J., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00008 · Cited by 66
Self-citationTREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response
Jiang, T., Zhang, Y., Gao, Q., Ou, Z., Gong, P., Shi, J., Wu, L., & Zhou, J. (2018) · Inflammation · doi:10.1007/s10753-018-0735-5 · Cited by 66
CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD
Gispert, J. D., Monté, G. C., Falcón, C., Tucholka, A., Rojas, S., Sánchez‐Valle, R., Antonell, A., Lladó, A., Rami, L., & Molinuevo, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.022 · Cited by 62
Sacher, C., Blume, T., Beyer, L., Peters, F., Eckenweber, F., Sgobio, C., Deussing, M., Albert, N. L., Unterrainer, M., Lindner, S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227322 · Cited by 51
Self-citationBrendel, M., Jaworska, A., Herms, J., Trambauer, J., Rötzer, C., Gildehaus, F.-J., Carlsen, J., Cumming, P., Bylund, J., Luebbers, T., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.74 · Cited by 50
Self-citationFocke, C., Blume, T., Zott, B., Shi, Y., Deußing, M., Peters, F., Schmidt, C., Kleinberger, G., Lindner, S., Gildehaus, F., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217703 · Cited by 50
Self-citationBlume, T., Focke, C., Peters, F., Deussing, M., Albert, N. L., Lindner, S., Gildehaus, F.-J., von Ungern-Sternberg, B., Ozmen, L., Baumann, K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1347-6 · Cited by 45
Self-citation
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“High CSF sTREM2 was associated with slower rates of A β accumulation, 187 and higher CSF sTREM2/p-Tau was associated with slower cognitive decline, 188 which supports the hypothesis that microglia and sTREM2 play a protective role in AD. sTREM2 is thought to be protective by (i) stimulating…”
ResultMicroglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
The role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 192
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
Metadata
- Authors
- Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., Shaw, L., Trojanowski, J. Q., Herms, J., Dichgans, M., (ADNI), T. A. D. N. I., Brendel, M., Haass, C., & Franzmeier, N.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- Ludwig-Maximilians-Universität München (DE)
- Pasqual Maragall Foundation (ES)
- University of Wisconsin–Madison (US)
- The University of Sydney (AU)
- Washington University in St. Louis (US)
- University of Pennsylvania (US)
- Institut für Schlaganfall- und Demenzforschung (DE)
- Corresponding author
- Ewers, Michael
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-08-10
- Volume
- 12
- Issue
- 9
- Pages
- e12308-e12308
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7507349
- OpenAlex
- W3047911986
- Cited by
- 133
- References
- 94
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 20 · 2020: 5
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- Funders
- LMUexcellent
- Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy, HA1737/16-1)
- HHS | National Institutes of Health (U01 AG024904)
- U.S. Department of Defense (W81XWH-12-2-0012)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- soluble TREM2, cerebrospinal fluid biomarkers, microglial activation, amyloid-beta deposition, Alzheimer's disease, amyloid PET, tau PET, neuroinflammation, amyloid plaques
- MeSH terms
- Alzheimer Disease, Animals, Humans, Membrane Glycoproteins, Receptors, Immunologic, Biomarkers, Amyloid beta-Peptides, tau Proteins, Microglia, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.